GLP-1s: The $200 Billion Flow and the Addiction Revenue Catalyst

The GLP-1 market is a multi-trillion dollar flow in motion. Its value stood at $94.06 billion in 2025 and is projected to more than double, reaching $216.12 billion by 2035. This represents an 8.8% compound annual growth rate over the next decade. The broader incretin market, which includes GLP-1s, is on a similar trajectory, with J.P. Morgan Research forecasting it will hit $200 billion by 2030.

This explosive growth is fueled by soaring demand for treating diabetes and obesity, conditions that continue to rise globally. The market is also being expanded by key innovations, most notably the recent approval of oral GLP-1 formulations. These new delivery methods are expected to open the market to millions more patients who may be hesitant to use injectables, significantly broadening the addressable patient base.

The scale of the patient uptake underscores the flow's magnitude. J.P. Morgan estimates that GLP-1 treatment in the U.S. will grow from around 10 million people in 2025 to 25 million by 2030. This isn't just a pharmaceutical trend; it's a massive, sustained cash flow into the healthcare and biotech sectors, driven by a powerful combination of disease prevalence and therapeutic innovation.

The Pricing Storm and Competitive Erosion

The market's explosive growth is being met with a fierce pricing storm. Novo Nordisk, the former leader, now expects its sales to fall between 5% and 13% this year. This forecast, driven by U.S. price pressures and patent expirations, has already triggered a brutal market reaction. The stock has lost nearly 50% of its value over the past year, erasing all gains for the year and wiping out most of its 2025 rally.

This financial erosion is a direct result of a major market share shift. Competition from Eli Lilly has accelerated, with Lilly now capturing an estimated 60% of the market compared to Novo's 40%. The primary catalyst is Lilly's Mounjaro, which has demonstrated superior clinical results. This competitive pressure is compounded by policy, as both companies have agreed to cut U.S. prices for their drugs, with Novo's average price dropping to around $350 per month from over $1,000.

The headwinds are structural. Beyond the immediate price cuts, Novo faces the loss of key patent protections for its core drug semaglutide in several countries, opening the door to cheaper generics. This combination of policy-driven price erosion, patent cliffs, and stiffer clinical competition is creating a powerful headwind that is currently overwhelming the market's top-line growth.

The New Revenue Catalyst: Addiction Treatment

A new study has uncovered a massive, previously unquantified flow: GLP-1 drugs could slash substance-related deaths and overdoses. The research, analyzing over 600,000 patients, found those taking the drugs had 50% fewer substance-related deaths and 39% fewer drug overdoses. This isn't just a clinical curiosity; it points to a potential new revenue catalyst by dramatically expanding the drugs' therapeutic footprint.

The financial implication is twofold. First, it suggests enormous healthcare cost savings by reducing emergency visits and hospitalizations linked to addiction. Second, and more directly, it creates a new, high-volume treatment indication. The study showed a 14% lower risk of developing addiction among patients with no prior history, indicating a preventive use case that could reach millions beyond current obesity and diabetes populations.

This data fundamentally shifts the market narrative. The focus is moving from treating metabolic conditions to addressing a core driver of addiction-craving itself. If confirmed, this could expand the addressable patient population exponentially, turning GLP-1s into a foundational therapy for a broad spectrum of substance use disorders. The flow of revenue is no longer just about weight and blood sugar; it's about a new, massive channel for chronic disease management.

Catalysts and Risks for the Flow

The market's cash flow is now caught between powerful catalysts and severe structural headwinds. The most immediate pressure is a new, explicit price cap. A White House agreement with Novo Nordisk and Eli Lilly will cap GLP-1 prices at no more than $350 per month for Medicare and Medicaid beneficiaries. This is a direct, policy-driven erosion of the premium pricing that fueled the initial boom.

Yet even with lower list prices, insurers are tightening coverage. Insurers are already raising cost-sharing and increasing use of prior authorization to restrict access. The fear is that lower drug prices will not translate to broader coverage; instead, payers may simply shift the financial burden to patients through higher copays and more stringent approval hurdles. This creates a significant friction point for patient uptake, potentially capping the flow of new revenue.

The most promising catalyst, the addiction treatment data, remains observational. While a large study found a 50% lower rate of substance-related deaths among GLP-1 users, the research cannot prove causation. For this new indication to drive insurance coverage and a new revenue stream, clinical trials are needed to confirm efficacy. Until then, it remains a high-potential but unproven narrative that could accelerate the market's expansion if validated.